Connection

Fengcai Zhu to Genetic Vectors

Back to Details
This is a "connection" page, showing publications Fengcai Zhu has written about Genetic Vectors.
Fengcai Zhu
Connection Strength
0.247
Genetic Vectors
  1. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
    View in: PubMed
    Score: 0.125
  2. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017 02 11; 389(10069):621-628.
    View in: PubMed
    Score: 0.098
  3. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017 03; 5(3):e324-e334.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.